非布索坦治什么？

What to treat? Research shows that febuxostat is clinically used for gout and gouty nephropathy. Febuxostat is effective in patients who are ineffective or intolerant to uricosuric drugs. Not recommended for use in asymptomatic hyperuricemia. 

Febuxostat is an effective non-purine selective inhibitor of xanthine oxidase XO. It achieves the therapeutic effect of reducing serum uric acid by selectively inhibiting xanthine oxidase. Uric acid is the end product of purine metabolism and is produced in the cascade reaction of hypoxanthine → xanthine → uric acid. Each step of the conversion is catalyzed by xanthine oxidase. Febuxostat has been shown to effectively inhibit both the oxidized and reduced forms of xanthine oxidase. Febuxostat at therapeutic concentrations does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotate monophosphate decarboxylase, or purine nucleoside phosphorylase. 

In addition, the U.S. Food and Drug Administration (FDA) issued a safety information warning for the gout drug febuxostat, believing that it may increase the risk of cardiovascular death and all-cause death. 

The FDA pointed out that patients who have failed or are intolerant to allopurinol can still use febuxostat, but doctors should inform patients of the cardiovascular risks of febuxostat and advise them to seek medical attention immediately if they develop the following symptoms: chest pain, shortness of breath, fast or irregular heartbeat, numbness or weakness on one side of the body, dizziness, difficulty speaking, or sudden severe headache. When the FDA approved febuxostat for clinical use in 2009, it added a warning about possible cardiovascular events to the prescription information. This update of the warning was based on the results of the post-marketing safety study CARES. The results of the study showed that although febuxostat did not increase the risk of the primary composite endpoint compared with allopurinol, it significantly increased the risk of cardiovascular death and all-cause death. For every 1,000 patients treated with febuxostat for 1 year, 15 cardiovascular deaths and 26 all-cause deaths occurred.

The above are the conditions that our Medical Companion Overseas Medical Consulting Service Company provides you with febuxostat treatment, which is clinically used for gout and gouty nephropathy. Patients who are ineffective or intolerant to uricosuric drugs.